Sera Prognostics (NASDAQ:SERA) Trading Up 11.5% – Here’s Why

Sera Prognostics, Inc. (NASDAQ:SERA)’s share price traded up 11.5% on Wednesday . The company traded as high as $2.06 and last traded at $2.03. 24,334 shares were traded during mid-day trading, a decline of 46% from the average session volume of 45,286 shares. The stock had previously closed at $1.82.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Craig Hallum assumed coverage on shares of Sera Prognostics in a research report on Thursday, June 4th. They set a “buy” rating and a $6.00 price target on the stock. Weiss Ratings cut Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Sera Prognostics currently has an average rating of “Moderate Buy” and a consensus target price of $5.50.

Sera Prognostics Price Performance

The stock’s fifty day moving average is $1.93 and its two-hundred day moving average is $2.40. The firm has a market capitalization of $78.32 million, a price-to-earnings ratio of -3.08 and a beta of 0.97.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.07 million. As a group, analysts anticipate that Sera Prognostics, Inc. will post -0.58 EPS for the current year.

Insider Transactions at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 20,755 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total value of $43,170.40. Following the completion of the sale, the chief executive officer directly owned 871,999 shares in the company, valued at approximately $1,813,757.92. This trade represents a 2.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 27,755 shares of company stock valued at $57,840. Company insiders own 11.30% of the company’s stock.

Institutional Trading of Sera Prognostics

Several institutional investors and hedge funds have recently bought and sold shares of SERA. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Sera Prognostics in the fourth quarter valued at approximately $31,000. Arkadios Wealth Advisors bought a new stake in Sera Prognostics in the 1st quarter valued at $25,000. Lido Advisors LLC acquired a new stake in Sera Prognostics during the 3rd quarter valued at $68,000. Cetera Investment Advisers acquired a new stake in Sera Prognostics during the 4th quarter valued at $74,000. Finally, Two Sigma Investments LP bought a new position in Sera Prognostics during the third quarter worth $97,000. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.